co-investments with the leading venture firms of the US and Europe: OrbiMed, Domain Associates, Canaan, ProQuest, LSP, Aisling Capital, MPM, Alta Partners, Frazier, Sofinnova, KPCB, as well as with the corporate venture firms: Pfizer, Roche, J&JDC, Novo, etc. Prioritized therapeutic areas are oncology, autoimmune diseases, rare diseases, and neurology. Our team members have extensive hands-on experience in product launches (over 40 products in the US and Europe), investments management (over $30 billion overall investment/liquidity), and exits of venture-backed companies.